Myeloma Novel Drug Targets and agents

Category: Myeloma Novel Drug Targets and agents

eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)

(PA-322) eMMpower: A Longitudinal Multi-Center Chart Review Consortium for Multiple Myeloma (MM)

Thursday, September 18, 2025

Rafael Fonseca, MD

Hematologist and Chief Innovation Officer
Mayo Clinic

Introduction: With the rapidly evolving treatment paradigm in MM, timely, high-quality, representative real-world evidence (RWE) is critical to inform clinical practice and advance MM care. However, existing real-world data (RWD) sources often lack clinical depth, physician-confirmed response, cytogenetics, and diversity in demographics and care setting needed for robust RWE generation. To address these gaps, the eMMpower consortium was established to provide a strong infrastructure with continual, long-term data collection in the US and a GenAI-enabled rapid analytics platform, to help expedite decision-making and evidence generation. In consultation with MM experts, eMMpower aims to deliver critical insights into MM care.

Methods:   eMMpower is a multi-site retrospective chart review consortium collecting clinically rich, longitudinal RWD that is reflective of demographics of patients with MM, geography, and practice type in the US. eMMpower gathers detailed patient characteristics, treatment patterns and sequencing, and outcomes across the MM care continuum—from frontline therapy in transplant-eligible (TE) and -ineligible (TIE) pts to later-lines of therapy where bispecific T-cell engagers and CAR-T are approved for use. A 5-year data collection plan with annual updates supports robust longitudinal analyses. The current target is 2,000 patients (pts) from 20 high-volume US centers and large health care systems. A clinician-led steering committee with rotating membership sets scientific priorities aligned with emerging clinically-relevant questions unanswered by clinical trials and other RWD with an emphasis on practice-informing RWE. Proposals are reviewed biannually by the committee and are selected based on scientific merit, feasibility, and translational impact.

Results:   As of 3/31/2025, 14 sites joined eMMpower, including 10 academic medical centers (2 Northeast; 3 Midwest; 2 South; 3 West), 3 community networks (2 National; 1 South), and a national patient advocacy organization. The 12-member steering committee approved 7 proposals in 12/2024 (3 frontline-focused, 4 later line-focused). Nine sites have begun data collection, among which 44% see ≥50 new MM pts/year, 68% offer SCT, and 89% offer CAR-T. To date, six sites have provided deidentified data on 499 pts: 260 TE pts on frontline therapy, 161 pts on teclistamab and 78 pts on talquetamab. Seventeen percent of included pts were African American. Data for other novel frontline and later-line treatments will also be collected in the future.

Conclusions:   eMMpower marks a major advancement in RWD collection for MM. Through diverse patient representation in demographics, geography, and practice type, varied clinical settings and robust longitudinal data, it offers a powerful platform for timely and clinically relevant insights through clinician-led research. eMMpower has the potential to redefine the role of RWD in MM—filling key evidence gaps, informing care, supporting innovation and raising treatment standards for patients.